Cytoreductive surgery (CRS) combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is an advanced and highly effective treatment for advanced ovarian cancer, particularly when it has spread to the peritoneum. CRS involves the removal of as much of the visible tumor as possible, while HIPEC delivers heated chemotherapy directly into the abdominal cavity. The heat helps the chemotherapy work more effectively, targeting even the smallest remaining cancer cells. This combined approach has proven successful in improving survival rates and reducing the chances of recurrence in patients with advanced-stage ovarian cancer. The precision and effectiveness of CRS + HIPEC are greatly enhanced by experienced surgeons, such as Dr. Rahul D. Modi, who specialize in this intricate procedure. His approach ensures that patients receive the best possible outcome through careful planning, meticulous surgery, and ongoing support. With these combined techniques, he helps to improve the prognosis for women diagnosed with advanced ovarian cancer, offering hope and better long-term survival prospects.